



ASX ANNOUNCEMENT

7 FEBRUARY 2022

HITI·IQ Awarded Australian Innovation Patent

- ✓ **HITI·IQ secures Australian Innovation Patent for its concussion management technology; and**
- ✓ **Patent provides protection for the proprietary calibration methods that underpin the high accuracy output that HITI·IQ technology delivers.**

Transformative, concussion management technology company, HITI·IQ Limited (ASX: HIQ) (HITI·IQ or the Company), is pleased to announce that it has secured an important Australian Innovation Patent for its leading concussion management technology.

Australian Innovation Patent

An Australian Innovation Patent (Patent No. 2021107528) has been awarded to HITI·IQ for “Technology Adapted To Facilitate User-Specific Calibration Of Instrumented Mouthguard Devices, Including Calibration Methods For Instrumented Mouthguard Devices”.

Key features of the patent awarded to HITI·IQ cover the specifics of how HITI·IQ instrumented mouthguard technology is calibrated for individual users which forms part of the proprietary process developed by the Company, including:

- Taking a 3D scan of the relevant player’s biometrics;
- Manufacturing a custom-formed mouthguard; and
- Using a proprietary calibration method to determine position and orientation of sensors.

The combined process determines the relationship between the position of the impact sensors relative to the orientation of the player’s head during impacts. The high value data collected is then fed into HITI·IQ’s artificial intelligence engine that delivers highly accurate data that customers rely on in their performance and player well-being programs. Being an Innovation Patent, the associated rights are especially robust to withstand validity attacks from third parties.

Global Opportunity

The newly awarded patent presents a significant milestone in HITI·IQ’s intellectual property development strategy as it targets the \$5 billion global addressable concussion management market. HITI·IQ’s patent portfolio currently comprises fourteen patent families, with numerous applications pending in various stages of the patent process globally. The portfolio continues to grow and expand, with five international PCT patent applications pending, and seven provisional applications lodged in the last year. The patent portfolio covers numerous facets of HITI·IQ’s technology framework, including hardware, manufacturing and calibration techniques, and data processing methods.

HITI·IQ Limited

ACN 609 543 213
ASX: HIQ

HITI·IQ.COM

Corporate Office

Level 2, 9-17 Raglan Street
South Melbourne VIC 3205

E: investors@hitiq.com

Directors

Otto Buttula	Non-Executive Chair
Michael Vegar	Managing Director
Phillip Carulli	Non-Executive Director
Glenn Smith	Non-Executive Director
Aidan Clarke	Non-Executive Director

Commenting on the IP protection, HITIQ CEO, Mike Vegar, said:

- *“Patents form an important element of our commercialisation strategy and we are pleased to have*
- *secured an Australian Innovation Patent covering a strategically important market for the Company.*
- *This patent will protect the commercial advantage we have built that allows us to provide highly*
- *accurate and sophisticated technology to our customers.*
- *We look forward to building upon this initial milestone with further additions to our patent portfolio as*
- *we focus on the massive \$5 billion global concussion management market.”*

- ENDS -

Authorised for release by the Board of Directors.

For more information, contact:

Mike Vegar	Elvis Jurcevic
CEO & MD	Investor Relations
HITIQ Limited	+61 408 268 271
investors@hitiq.com	ej@hitiq.com

About HITIQ

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company's products support the identification, monitoring and management of sport related brain injury. HITIQ's product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company's first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.